Low-dose sirolimus in retroperitoneal lymphangioleiomyomas

Kamonpun Ussavarungsi, Archana T. Laroia, Charles D. Burger

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Lymphangioleiomyomatosis (LAM) is a rare disease associated with cystic lung destruction and abdominal tumors, including lymphangioleiomyomas, which frequently occur in the retroperitoneal region. Sirolimus therapy is currently recommended for LAM patients with abnormal or declining lung function with an adjusted dose to maintain a serum trough level of 5-15 ng/mL. We describe a significant reduction of retroperitoneal lymphangioleiomyomas after treatment with low-dose sirolimus therapy (serum trough level <5 ng/mL) in a patient with sporadic LAM.

Original languageEnglish (US)
Pages (from-to)349-352
Number of pages4
JournalLung India
Issue number4
StatePublished - Jul 1 2019


  • Low-dose sirolimus
  • Lymphangioleimyomas
  • Lymphangioleiomyomatosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Low-dose sirolimus in retroperitoneal lymphangioleiomyomas'. Together they form a unique fingerprint.

Cite this